Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer.
Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291-295. © 2016 Wiley Periodicals, Inc.
Pancreatic Cancer Program, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
Elliot A
EA
Asare
Pancreatic Cancer Program, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
Douglas B
DB
Evans
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Beth A
BA
Erickson
Division of Gastroenterology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Murad
M
Aburajab
Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Parag
P
Tolat
Pancreatic Cancer Program, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
Susan
S
Tsai
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006801:Humans; D020360:Neoadjuvant Therapy; D017063:Outcome Assessment, Health Care; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents
cost-effectiveness; healthcare value; neoadjuvant therapy; pancreatic cancer